Thomas Newsom-Davis

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Time-Dependent COVID-19 Mortality in Patients With Cancer

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases